Advertisement


Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments

ESMO 2018 Congress

Advertisement

Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and monitor toxicities.



Related Videos

Skin Cancer
Immunotherapy

Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights

Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.

Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as targeted therapy for biliary cancer.

Lung Cancer
Immunotherapy

Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights

Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for small–cell lung cancer as well as unresectable NSCLC.

Bladder Cancer
Kidney Cancer
Immunotherapy

Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy

Cora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-025 study on nivolumab vs everolimus for mRCC; the CheckMate-214 study on nivolumab, ipilimumab, and sunitinib for treatment-naive advanced or metastatic clear-cell RCC; and immunotherapy for urothelial cancer for both first- line cisplatin-ineligible and second-line therapy after cisplatin chemotherapy.

Skin Cancer
Symptom Management

Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities

Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especially endocrine and neurologic side effects, which can require lifetime hormone replacement and may cause permanent dysfunction.

Advertisement

Advertisement



Advertisement